SII联合TyG指数在低密度脂蛋白达标的急性 心肌梗死患者中的预测价值
Predictive Value of Combined SII and TyG Index in Acute Myocardial Infarction Patients with Achieved LDL-C Targets
摘要: 目的:探讨系统性免疫炎症指数(SII)联合甘油三酯–葡萄糖指数(TyG)在LDL-C < 1.4 mmol/L急性心肌梗死(AMI)患者中的预后预测价值。方法:回顾性纳入2012~2023年间诊断为AMI且LDL-C < 1.4 mmol/L的患者620例。主要终点为住院期间全因死亡。采用多因素Logistic回归分析评估SII和TyG与死亡的关系,限制性立方样条(RCS)分析探索非线性关系,采用ROC曲线分析SII联合TyG指数对低密度脂蛋白达标的急性心肌梗死患者院内死亡的预测价值。P < 0.05表示差异有统计学意义。结果:620例患者中,院内死亡43例(6.9%)。SII最高四分位数(Q4)与最低四分位数(Q1)相比,死亡风险显著升高(未调整OR = 6.24,95% CI:2.10~18.58;多因素调整后OR = 5.83,P < 0.001)。TyG各四分位数与死亡风险无显著关联(P > 0.05)。联合分组分析显示,高SII + 低TyG组死亡风险最高(OR = 5.89, 95% CI: 1.41~24.72, P = 0.015)。RCS分析显示SII与死亡风险呈非线性关系(P = 0.0287),而TyG呈近似线性关系。结论:SII是LDL-C < 1.4 mmol/L的AMI患者院内死亡的独立预测因子且与死亡风险呈非线性关系。SII-TyG联合分组可有效识别高危人群,高SII + 低TyG组死亡风险最高。
Abstract: Objective: To explore the prognostic predictive value of systemic immune-inflammation index (SII) combined with triglyceride-glucose index (TyG) in patients with acute myocardial infarction (AMI) and low-density lipoprotein cholesterol (LDL-C) < 1.4 mmol/L. Methods: A total of 620 patients diagnosed with AMI and LDL-C < 1.4 mmol/L from 2012 to 2023 were retrospectively enrolled. The primary endpoint was in-hospital all-cause mortality. Multivariate Logistic regression analysis was used to evaluate the correlation between SII, TyG and mortality. Restricted cubic spline (RCS) analysis was applied to explore the nonlinear correlation. ROC curve was adopted to analyze the predictive efficacy of combined SII and TyG for in-hospital death in AMI patients achieving LDL-C target. A P value < 0.05 was considered statistically significant. Results: Among 620 patients, 43 cases (6.9%) died during hospitalization. Compared with the lowest quartile (Q1), the highest SII quartile (Q4) presented significantly higher mortality risk (unadjusted OR = 6.24, 95% CI: 2.10~18.58; adjusted OR = 5.83, P < 0.001). No significant correlation was found between TyG quartiles and mortality risk (P > 0.05). Combined stratified analysis showed that patients in high SII plus low TyG group carried the highest mortality risk (OR = 5.89, 95% CI: 1.41~24.72, P = 0.015). RCS analysis revealed a nonlinear relationship between SII and mortality risk (P = 0.0287), while TyG showed an approximately linear relationship. Conclusion: SII is an independent predictor, demonstrating a nonlinear relationship of in-hospital mortality in AMI patients with LDL-C < 1.4 mmol/L. Combined SII-TyG stratification can effectively identify high-risk populations, and patients with high SII and low TyG have the highest adverse prognosis risk.
文章引用:许家超, 于海初. SII联合TyG指数在低密度脂蛋白达标的急性 心肌梗死患者中的预测价值[J]. 临床医学进展, 2026, 16(6): 1187-1199. https://doi.org/10.12677/acm.2026.1662326

参考文献

[1] Roth, G.A., Mensah, G.A., Johnson, C.O., Addolorato, G., Ammirati, E., Baddour, L.M., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 1990-2019 Study. Journal of the American College of Cardiology, 76, 2982-3021. [Google Scholar] [CrossRef] [PubMed]
[2] Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188. [Google Scholar] [CrossRef] [PubMed]
[3] Sabouret, P., Lpc, F., Bordenave, L., et al. (2021) Residual Cardiovascular Risk: Definition, Clinical Relevance, and Therapeutic Perspectives. Current Medical Research and Opinion, 37, 321-332.
[4] Ridker, P.M. (2016) From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection. Circulation Research, 118, 145-156. [Google Scholar] [CrossRef] [PubMed]
[5] Khera, A.V., Won, H.H., Peloso, G.M., Lawson, K.S., Bartz, T.M., Deng, X., et al. (2016) Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia. Journal of the American College of Cardiology, 67, 2578-2589. [Google Scholar] [CrossRef] [PubMed]
[6] Min, J.K. (2021) Effect of Achieved Low-Density Lipoprotein Cholesterol Level on Residual Cardiovascular Risk. Current Opinion in Lipidology, 32, 307-315.
[7] Cheng, K., Chu, C., Lin, T., Lee, K., Sheu, S. and Lai, W. (2015) Lipid Paradox in Acute Myocardial Infarction—The Association with 30-Day In-Hospital Mortality. Critical Care Medicine, 43, 1255-1264. [Google Scholar] [CrossRef] [PubMed]
[8] Emerging Risk Factors Collaboration, Kaptoge, S., Di Angelantonio, E., et al. (2010) C-Reactive Protein Concentration and Risk of Coronary Heart Disease, Stroke, and Mortality: An Individual Participant Meta-Analysis. The Lancet, 375, 132-140.
[9] Ye, Z., Hu, T., Wang, J., et al. (2022) Systemic Immune-Inflammation Index as a Potential Biomarker of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, 933913. [Google Scholar] [CrossRef] [PubMed]
[10] Sun, W., Chen, Z. and Luo, Y. (2025) Association between Systemic Immune-Inflammation Index and Outcomes of Acute Myocardial Infarction: A Systemic Review and Meta-Analysis. Surgical Infections, 26, 183-194. [Google Scholar] [CrossRef] [PubMed]
[11] Guerrero-Romero, F., Simental-Mendía, L.E., González-Ortiz, M., Martínez-Abundis, E., et al. (2010) The Product of Triglycerides and Glucose, a Simple Measure of Insulin Sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp. The Journal of Clinical Endocrinology & Metabolism, 95, 3347-3351. [Google Scholar] [CrossRef] [PubMed]
[12] Tao, L.C., Xu, J.N., Wang, T.T., et al. (2022) Triglyceride-Glucose Index as a Marker in Cardiovascular Diseases. Cardiovascular Diabetology, 21, Article Number 68. [Google Scholar] [CrossRef] [PubMed]
[13] Sun, C., Hu, L., Li, X., et al. (2024) Triglyceride-Glucose Index’s Link to Cardiovascular Outcomes Post-Percutaneous Coronary Intervention in China: A Meta-Analysis. ESC Heart Failure, 11, 1317-1328. [Google Scholar] [CrossRef] [PubMed]
[14] Hotamisligil, G.S. (2006) Inflammation and Metabolic Disorders. Nature, 444, 860-867. [Google Scholar] [CrossRef] [PubMed]
[15] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019) [J]. 中华心血管病杂志, 2019, 47(10): 766-783.
[16] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非ST段抬高型急性冠脉综合征诊断和治疗指南(2024) [J]. 中华心血管病杂志, 2024, 52(6): 615-646.
[17] Yang, Y.L., Wu, C.H., Hsu, P.F., Chen, S., Huang, S., Chan, W.L., et al. (2020) Systemic Immune‐Inflammation Index (SII) Predicted Clinical Outcome in Patients with Coronary Artery Disease. European Journal of Clinical Investigation, 50, e13230. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, Y., Li, S., Xu, R.X., et al. (2021) Systemic Immune-Inflammation Index Is Associated with Disease Severity and Poor Clinical Outcomes in Patients with Acute Myocardial Infarction. Biomarkers in Medicine, 15, 1303-1314.
[19] Hu, B., Yang, X., Xu, Y., Sun, Y., Sun, C., Guo, W., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222. [Google Scholar] [CrossRef] [PubMed]
[20] Bonaventura, A., Montecucco, F., Dallegri, F., et al. (2019) Novel Findings in Neutrophil Biology and Their Impact on Cardiovascular Disease. Cardiovascular Research, 115, 1266-1285. https://pubmed.ncbi.nlm.nih.gov/30918936/ [Google Scholar] [CrossRef] [PubMed]
[21] Chia, S., Nagurney, J.T., Brown, D.F.M., Raffel, O.C., Bamberg, F., Senatore, F., et al. (2009) Association of Leukocyte and Neutrophil Counts with Infarct Size, Left Ventricular Function and Outcomes after Percutaneous Coronary Intervention for St-Elevation Myocardial Infarction. The American Journal of Cardiology, 103, 333-337. [Google Scholar] [CrossRef] [PubMed]
[22] Dhabhar, F.S. (2009) Enhancing versus Suppressive Effects of Stress on Immune Function: Implications for Immunoprotection and Immunopathology. Neuroimmunomodulation, 16, 300-317. [Google Scholar] [CrossRef] [PubMed]
[23] Zouridakis, E.G., Garcia-Moll, X., Kaski, J.C., et al. (2000) Usefulness of the Blood Lymphocyte Count in Predicting Recurrent Instability and Death in Patients with Unstable Angina Pectoris. American Journal of Cardiology, 86, 449-451. [Google Scholar] [CrossRef
[24] Gawaz, M., Langer, H. and May, A.E. (2005) Platelets in Inflammation and Atherogenesis. Journal of Clinical Investigation, 115, 3378-3384. [Google Scholar] [CrossRef] [PubMed]
[25] Jolly, S.S., Shenkman, B., Bhavsar, S., et al. (2009) Systematic Review of the Prognostic Importance of Markers of Systemic Inflammation in Acute Coronary Syndromes. Canadian Journal of Cardiology, 25, 471-478.
[26] Liu, X., Tan, Z., Huang, Y., et al. (2022) Relationship between the Triglyceride-Glucose Index and Risk of Cardiovascular Diseases and Mortality in the General Population: A Systematic Review and Meta-Analysis. Cardiovascular Diabetology, 21, Article Number 124. [Google Scholar] [CrossRef] [PubMed]
[27] Liu, H., Wang, L., Wang, H., et al. (2024) The Association of Triglyceride-Glucose Index with Major Adverse Cardiovascular and Cerebrovascular Events after Acute Myocardial Infarction: A Meta-Analysis of Cohort Studies. Nutrition & Diabetes, 14, Article Number: 39. [Google Scholar] [CrossRef] [PubMed]
[28] Capes, S.E., Hunt, D., Malmberg, K. and Gerstein, H.C. (2000) Stress Hyperglycaemia and Increased Risk of Death after Myocardial Infarction in Patients with and without Diabetes: A Systematic Overview. The Lancet, 355, 773-778. [Google Scholar] [CrossRef] [PubMed]
[29] Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., et al. (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 377, 1119-1131. [Google Scholar] [CrossRef] [PubMed]